+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

PT010

  • ID: 4775194
  • Report
  • July 2018
  • Region: Global
  • 20 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
PT010 is a fixed triple-combination product consisting of a long-acting muscarinic antagonist (LAMA [glycopyrrolate]), a long-acting beta 2 agonist (LABA [formoterol]), and an inhaled corticosteroid (ICS [budesonide]). PT010 is in Phase III development for the treatment of moderate to very severe COPD, and in Phase II development for the treatment of moderate to severe persistent asthma.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
PT010: Chronic obstructive pulmonary disease (COPD)

LIST OF FIGURES
Figure 1: PT010 for COPD – SWOT analysis
Figure 2: The authors drug assessment summary of PT010 for COPD
Figure 3: The authors drug assessment summary of PT010 for COPD
Figure 4: PT010 sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: PT010 drug profile
Table 2: PT010 Phase III data in COPD
Table 3: PT010 Phase III trials in COPD
Table 4: PT010 sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll